Grant: CIHR Fellowship
Direct Payment
$150,000.00
Drug design principles for nicotinic acetylcholine receptor-channels
FY 2010-11
Summary
Synapses are the primary points of communications in the nervous system. Nicotinic acetylcholine receptor-channels (AChRs) are involved in the fast transmission of signals at nerve-nerve and nerve-muscle synapses. Small molecules, called agonists, bind to and activate AChRs causing them to open and conduct ions across the cell membrane, which eventually initiates a physiological response. Nicotine, an AChR agonist, is responsible for the addictive properties of tobacco smoking, which leads to cancer, heart disease, and stroke. Over 5 million smoking-related deaths worldwide annually are the largest source of preventable mortality. AChRs contain binding sites for drugs that potentially could treat nicotine addiction, epilepsy, muscle weakness disorders, schizophrenia, Parkinson's disease, and autism. The key to designing efficient drugs for AChRs is to understand the detailed mechanism by which agonists bind to and activate AChRs. However, previous studies with AChR agonists encountered technical problems and where unable to measure the full action of the drugs. Recently, we developed a new experimental approach to overcome these problems and, for the first time, to allow us to precisely and directly measure the action of AChR agonists. Using this new electrophysiology technique, we will measure and compare the binding and activation properties of novel AChR agonists. We plan to test these molecules on both the native and mutant AChRs. This will provide us with a map of specific atom-atom interactions (between the drug and AChR) as related to drug binding or AChR activation. To visualize the site of drug action, we will build a model of the AChR using sophisticated molecular modelling methods and supercomputers, which will guide further experiments and explain our findings. Our study will help improve the design of new pharmaceuticals by providing valuable information about the molecular events occurring at the drug binding site of AChRs.
Department
Program
CIHR Fellowship
Recipient
Location
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
214708
Name
Bruhova Iva
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Drug design principles for nicotinic acetylcholine receptor-channels
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Acetylcholine Receptor; Channel Gating; Drug Binding; Drug Design; Kinetic Analysis; Ligand-Receptor Interactions; Molecular Modelling; Monte Carlo-Energy Minimization; Protein Engineering; Single-Channel Electrophysiology
Abstract
Synapses are the primary points of communications in the nervous system. Nicotinic acetylcholine receptor-channels (AChRs) are involved in the fast transmission of signals at nerve-nerve and nerve-muscle synapses. Small molecules, called agonists, bind to and activate AChRs causing them to open and conduct ions across the cell membrane, which eventually initiates a physiological response. Nicotine, an AChR agonist, is responsible for the addictive properties of tobacco smoking, which leads to cancer, heart disease, and stroke. Over 5 million smoking-related deaths worldwide annually are the largest source of preventable mortality. AChRs contain binding sites for drugs that potentially could treat nicotine addiction, epilepsy, muscle weakness disorders, schizophrenia, Parkinson's disease, and autism. The key to designing efficient drugs for AChRs is to understand the detailed mechanism by which agonists bind to and activate AChRs. However, previous studies with AChR agonists encountered technical problems and where unable to measure the full action of the drugs. Recently, we developed a new experimental approach to overcome these problems and, for the first time, to allow us to precisely and directly measure the action of AChR agonists. Using this new electrophysiology technique, we will measure and compare the binding and activation properties of novel AChR agonists. We plan to test these molecules on both the native and mutant AChRs. This will provide us with a map of specific atom-atom interactions (between the drug and AChR) as related to drug binding or AChR activation. To visualize the site of drug action, we will build a model of the AChR using sophisticated molecular modelling methods and supercomputers, which will guide further experiments and explain our findings. Our study will help improve the design of new pharmaceuticals by providing valuable information about the molecular events occurring at the drug binding site of AChRs.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Bruhova, Iva
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~